Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Real-world outcomes in thoracic cancer patients with severe Acute respiratory syndrome Coronavirus 2 (COVID-19): Single UK institution experience.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Contributors:
      Minchom, Anna
    • Publication Information:
      Elsevier BV
    • Publication Date:
      2023
    • Collection:
      The Institute of Cancer Research (ICR): Publications Repository
    • Subject Terms:
    • Abstract:
      BACKGROUND: UK COVID-19 mortality rates are amongst the highest globally. Controversy exists on the vulnerability of thoracic cancer patients. We describe the characteristics and sequelae of patients with thoracic cancer treated at a UK cancer centre infected with COVID-19. METHODS: Patients undergoing care for thoracic cancer diagnosed with COVID-19 (RT-PCR/radiology/clinically) between March-June 2020 were included. Data were extracted from patient records. RESULTS: Thirty-two patients were included: 14 (43%) diagnosed by RT-PCR, 18 (57%) by radiology and/or convincing symptoms. 88% had advanced thoracic malignancies. Eleven of 14 (79%) patients diagnosed by RT-PCR and 12 of 18 (56%) patients diagnosed by radiology/clinically were hospitalised, of which four (29%) and 2 (11%) patients required high-dependency/intensive care respectively. Three (21%) patients diagnosed by RT-PCR and 2 (11%) patients diagnosed by radiology/clinically required non-invasive ventilation; none were intubated. Complications included pneumonia and sepsis (43% and 14% respectively in patients diagnosed by RT-PCR; 17% and 11% respectively in patients diagnosed by radiology/clinically). In patients receiving active cancer treatment, therapy was delayed/ceased in 10/12 (83%) and 7/11 (64%) patients diagnosed by RT-PCR and radiology/clinically respectively. Nine (28%) patients died; all were smokers. Median time from symptom onset to death was 7 days (range 3-37). CONCLUSIONS: The immediate morbidity from COVID-19 is high in thoracic cancer patients. Hospitalisation and treatment interruption rates were high. Improved risk-stratification models for UK cancer patients are urgently needed to guide safe cancer-care delivery without compromising efficacy.
    • File Description:
      Print-Electronic; application/pdf
    • ISSN:
      2468-2942
    • Relation:
      100261; S2468-2942(20)30096-4; Cancer Treatment and Research Communications, 2020, 25 pp. 100261 -; https://repository.icr.ac.uk/handle/internal/5711
    • Accession Number:
      10.1016/j.ctarc.2020.100261
    • Online Access:
      https://repository.icr.ac.uk/handle/internal/5711
      https://doi.org/10.1016/j.ctarc.2020.100261
    • Rights:
      https://creativecommons.org/licenses/by-nc-nd/4.0/
    • Accession Number:
      edsbas.5075D96D